ReviewCells2020
Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Risk factors for the mortality of hepatitis B virus-associated acute-on-chronic liver failure: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.Alimentary pharmacology & therapeutics · 2022Trial
- Article
- Acute-on-Chronic Liver Failure: An Eroded Cliff Hit by a Storm-A Narrative Review.International journal of molecular sciences · 2026Review
- [Analyzing research advances in single-cell sequencing technology for immunopathological mechanisms in acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Association between metabolic syndrome and 90-day mortality in acute-on-chronic liver failure patients based on propensity score matching and prognostic model construction.BMC gastroenterology · 2026Article
- A Systemic Inflammation Response Index (SIRI)-based nomogram for predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure: a retrospective cohort study.BMC gastroenterology · 2026Article
- Acute-on-chronic liver failure and immune dysregulation: Systemic inflammation and immunoparesis paradox.Hepatology communications · 2026Review
- miR-19b-3p engineered adipose-derived stem cell exosomes attenuate acute liver failure via promoting tissue repair and microenvironment remodeling.Materials today. Bio · 2026Article
- Neutrophil immunometabolism in ACLF and sepsis: mechanisms, dysfunction, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Single-Cell Analysis of Hepatic Non-Parenchymal Cells Reveals Endothelial Dysfunction and Altered Endothelial and B Cell Communication in Acute-on-Chronic Liver Failure.Journal of immunology research · 2026Article
- Etiology-Specific Nomograms for Predicting First Variceal Bleeding in Decompensated HBV- and HCV-Related Cirrhosis.International journal of general medicine · 2026Article
- HBV RNA dynamics and cytokine-driven hyperinflammation: a synergistic prognostic axis in hepatitis B-related acute-on-chronic liver failure.Frontiers in cellular and infection microbiology · 2026Article
- Risk factors analysis for progression to severe hepatitis in acute hepatitis E: a retrospective study of 146 hospitalized cases.BMC infectious diseases · 2025Article
- Prognostic value of inflammatory cytokine levels, clinical efficacy, and prognosis of the hybrid artificial liver support system in chronic liver failure treatment.Journal of medical biochemistry · 2025Article
- Bioinformatics identification of key genes correlating NOD1 and Endoplasmic Reticulum stress in Hepatitis B virus-induced acute liver failure.Scientific reports · 2025Article
- T cell dysregulation reflects disease stage in hepatitis virus and alcohol-related liver disease.Scientific reports · 2025Article
- Phase characteristics and risk factors of acute-on-chronic liver failure with invasive pulmonary aspergillosis.BMC infectious diseases · 2025Article
- Prognostic value of dynamic changes in C-reactive protein to albumin ratio in patients with acute-on-chronic liver failure.World journal of hepatology · 2025Article
- Impact of artificial liver plasma perfusion combined with plasma exchange therapy on clinical efficacy and short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure with or without HIV infection.BMC infectious diseases · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute-on-chronic liver failure (ACLF) is a complex syndrome that develops in patients with cirrhosis and is characterized by acute decompensation, organ failure(s) and high short-term mortality. ACLF frequently occurs in close temporal relationship to a precipitating event, such as acute alcoholic, drug-induced or viral hepatitis or bacterial infection and, in cases without precipitating events, probably related to intestinal translocation of bacterial products. Dysbalanced immune function is central to its pathogenesis and outcome with an initial excessive systemic inflammatory response that drives organ failure and mortality. This hyperinflammatory state ultimately impairs the host defensive mechanisms of immune cells, rendering ACLF patients immunocompromised and more vulnerable to secondary infections, and therefore to higher organ dysfunction and mortality. In this review, we describe the prevailing characteristics of the hyperinflammatory state in patients with acutely decompensated cirrhosis developing ACLF, with special emphasis on cells of the innate immune system (i.e., monocytes and neutrophils), their triggers (pathogen- and damage-associated molecular patterns [PAMPs and DAMPs]), their effector molecules (cytokines, chemokines, growth factors and bioactive lipid mediators) and the consequences on tissue immunopathology. In addition, this review includes a chapter discussing new emerging therapies based on the modulation of leukocyte function by the administration of pleiotropic proteins such as albumin, Toll-like receptor 4 antagonists, interleukin-22 or stem cell therapy. Finally, the importance of finding an appropriate intervention that reduces inflammation without inducing immunosuppression is highlighted as one of the main therapeutic challenges in cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.